Headshot of Maurizio Scaltriti

I lead a team of translational scientists who work on the whole solid tumour portfolio. We study tumour biology and mechanism of action and resistance to drive innovation in clinical trial design and accelerate clinical decision making with cutting-edge technologies. We provide the scientific rationale for the design of novel combinatorial strategies and identification of biomarkers of response to therapy.

Before joining AstraZeneca in October 2020, I was an Associate Professor and the Associate Director of Translational Science at Memorial Sloan Kettering Cancer Center. In this role, I worked closely with early drug development physicians – enabling new findings and hypotheses from the clinic to be quickly validated in the laboratory setting.

My research interests have been focused on elucidating tumour vulnerabilities to improve patient selection and how the selective pressure imposed by targeted therapy impacts drug resistance. Highlights from my early research include the identification of resistance mechanisms to PI3K inhibitors and to anti-HER2 therapy. I also worked on the characterisation of actionable genomic alterations found in solid tumours that prompted the testing of novel therapeutic strategies.


I am passionate about bridging the gap between the clinic and the laboratory to bring new treatment options to patients with cancer

Maurizio Scaltriti Vice President, Translational Medicine, Early Oncology

2015

Tory Burch Award (Breast Cancer Research Foundation)

2014

AACR Early Career Speaker Award (NextGen Star)

2010

AACR-Susan G. Komen Scholar-in-Training Award

Headshot of Maurizio Scaltriti

CURRENT ROLE

Joined Astrazeneca as Vice President, Translational Medicine, Early Oncology

2020

Joined AstraZeneca as Vice President of Translational Medicine, Early Oncology, Oncology R&D

2016

Appointed Associate Director of Translational Science of the Center for Molecular-Based Therapy, Memorial Sloan Kettering Cancer Center

2013

Joined Memorial Sloan Kettering Cancer Center as an Assistant Professor

Career highlights


2009, 2015

Companion diagnostic tests approved for activating mutations of EGFR-TK to guide therapy in lung cancer



Featured publications